Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 32572266.
- Also identified by DOI 10.1038/s41591-020-0933-1 and PMC identifier 8288043.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Improving early cancer detection has the potential to substantially reduce cancer-related mortality. Cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) is a highly sensitive assay capable of detecting early-stage tumors. We report accurate classification of patients across all stages of renal cell carcinoma (RCC) in plasma (area under the receiver operating characteristic (AUROC) curve of 0.99) and demonstrate the validity of this assay to identify patients with RCC using urine cell-free DNA (cfDNA; AUROC of 0.86).
Medical subject headings
- Carcinoma, Renal Cell
- DNA Methylation
- Early Detection of Cancer